Polymorphism of host response genes: Implications in the pathogenesis and treatment of acute renal failure

Kidney International

Volumn 67, Issue 1, 2005, Pages 14-33

  Jaber, Bertrand L ^a   Pereira, Brian J G ^b   Bonventre, Joseph V ^b   Balakrishnan, Vaidyanathapuram S ^b  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b NONE

Author keywords

Acute renal failure; Chemokines; Critical illness; Cytokines; Heat shock proteins; Infection; Inflammation; Mortality; Sepsis; Toll like receptors

Indexed keywords

NITRIC OXIDE; TUMOR NECROSIS FACTOR;

ACUTE KIDNEY FAILURE; CHEMOKINE GENE; COMPENSATORY ANTIINFLAMMATORY RESPONSE SYNDROME; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GENE; GENE LOCUS; GENETIC EPIDEMIOLOGY; GENETIC IDENTIFICATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITY; HO 1 GENE; HSP GENE; HUMAN; IL 1 GENE; IL 10 GENE; IL 6 GENE; IMMUNE RESPONSE; INFLAMMATION; KIDNEY ISCHEMIA; NEPHROTOXICITY; NOS GENE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYNDROME DELINEATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TH1 CELL; TH2 CELL; TLR GENE; TNF GENE;

EID: 10944235905     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00051.x     Document Type: Article

References (214)

1. NASH K, HAFEEZ A, HOU S: Hospital-acquired renal insufficiency. Am J Kidney Dis 39:930-936, 2002
2. NOLAN CR, ANDERSON RJ: Hospital-acquired acute renal failure. J Am Soc Nephrol 9:710-718, 1998
3. LEVY EM, VISCOLI CM, HORWITZ RI: The effect of acute renal failure on mortality: A cohort analysis. JAMA 275:1489-1494, 1996
4. CHERTOW GM, LEVY EM, HAMMERMEISTER KE, et al: Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 104:343-348, 1998
5. VENTER J, ADAMS M, MYERS E: The sequence of the human genome. Science 291:1304-1351, 2001
6. GUTTMACHER A, COLLINS F: Genomic medicine: Genomic medicine-A primer. N Engl J Med 347:1512-1520, 2002
7. BIDWELL J, KEEN L, GALLAGHER G, et al: Cytokine gene polymorphism in human disease: On-line databases, supplement 1. Genes Immunol 2:61-70, 2001
8. HAUKIM N, BIDWELL J, SMITH A, et al: Cytokine gene polymorphism in human disease: On-line databases, supplement 2. Genes Immunol 3:313-330, 2002
9. GENETIC VARIATION IN INDIVIDUALS: Mutation and Polymorphism, in Thompson & Thompson Genetics in Medicine (6th ed), edited by Nussbaum R, McInnes R, Willard H, Sixth ed, Philadelphia, WB Saunders Company, 2001, pp 79-94
10. VAN DEVENTER S: Cytokine and cytokine receptor polymorphisms in infectious disease. Intensive Care Med 26(Suppl 1):S98-S102, 2000
11. AMERICAN COLLEGE OF CHEST PHYSICIANS/SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE: Definitions of sepsis and organ failure and guidelines for the use of innovative therapies is sepsis. Crit Care Med 20:864-874, 1992
12. JABER BL, PEREIRA BJG: Inflammatory mediators in sepsis: Rationale for extracorporeal therapies. Am J Kidney Dis 28:S35-S49, 1996
13. MARTIN GS, MANNING DM, EATON S, MOSS M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554, 2003
14. GABAY C, KUSHNER I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454, 1999
15. KOCH T: Origin and mediators involved in sepsis and the systemic inflammatory response syndrome. Kidney Int 53 (Suppl 64):S66-S69, 1998
16. PINSKY MR VINCENT JL, DEVIERE J, et al: Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103:565-575, 1993
17. CASEY LC BR, BONE RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771-778, 1993
18. OPAL S, DEPALO V: Anti-inflammatory cytokines. Chest 117:1162-1172, 2000
19. OPAL SM, HUBER C: The role of interleukin-10 in critical illness. Curr Opin Infect Dis 13:221-226, 2000
20. VAN DER POLL T, JANSEN J, LEVI M, et al: Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 180:1985-1988, 1994
21. DONNELLY RP, FREEMAN SL, HAYES MP: Inhibition of IL-10 expression by IFN-γ up-regulates transcription of TNF-α in human monocytes. J Immunol 155:1420-1427, 1995
22. TABARDEL Y, DUCHATEAU J, SCHMARTZ D, et al: Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 119:76-80, 1996
23. FILLINGER MP, RASSIAS AJ, GUYRE PM, et al: Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery. J Cardiothorac Vasc Anesth 16:163-169, 2002
24. AREND WP, SMITH MFJ, JANSON RW, JOSLIN FG: IL-1 receptor antagonist and IL-1b producton in human monocytes are regulated differently. J Immunol 147:1530-1536, 1991
25. AREND W, MALYAK M, GUTHRIDGE C, GABAY C: Interleukin-1 receptor antagonist: Role in biology. Annu Rev Immunol 16:27-55, 1998
26. PEREIRA BJ: Cytokine production in patients on dialysis. Blood Purif 13:135-146, 1995
27. ZIMMER S, POLLARD V, MARSHALL G, et al: Effects of endotoxin on the Th1/Th2 response in humans. J Burn Care Rehab 17:491-496, 1996
28. TIPPING P, HOLDSWORTH S: T cells in glomerulonephritis. Springer Semin Immunopathol 24:377-393, 2003
29. WIECEK A, ZEIER M, RITZ E: Role of infection in the genesis of acute renal failure. Nephrol Dial Transplant 9:40-44, 1994
30. SANTOS OFP, BOIM MA, SCHOR N: Acute renal failure and sepsis-Pathophysiology. Kidney: A Current Survey of World Literature 4:59-62, 1995
31. CUNNINGHAM P, DYANOV H, PARK P, et al: Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 168:5817-5823, 2002
32. FLO TH, HALAAS O, TORP S, et al: Differential expression of toll-like receptor 2 in human cells. J Leukoc Biol 69:474-481, 2001
33. DYBDAHL B, WAHBA A, LIEN E, et al: Inflammatory response after open heart surgery: Release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 105:685-690, 2002
34. BONVENTRE J, WEINBERG J: Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 14:2199-2210, 2003
35. LINAS SL, WHITTEBURG D, PARSONS PE, et al: Mild renal ischemia activates primed neutrophils to cause acute renal failure. Kidney Int 42:610-616, 1992
36. ZOJA C, ANGIOLETTI S, DONADELLI R, et al: Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int 62:846-856, 2002
37. SOLEZ K, MOREL-MAROGER L, SRAER J-D: The morphology of acute tubular necrosis in man: Analysis of 57 renal biopsis and a comparision with glycerol model. Medicine 58:362-376, 1979
38. DENG J, KOHDA Y, CHIAO H, et al: Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 60:2118-2128, 2001
39. RAMESH G, REEVES W: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835-842, 2002
40. BURNE-TANEY M, KOFLER J, YOKOTA N, et al: Acute renal failure after whole body ischemia is characterized by inflammation and T cell-mediated injury. Am J Physiol Renal Physiol 285:F87-F94, 2003
41. SUNG F, ZHU T, AU-YEUNG K, SIOW YOK: Enhanced MCP-1 expression during ischemia/reperfusion injury is mediated by oxidative stress and NF-kappaB. Kidney Int 62:1160-1170, 2002
42. KARSOU S, JABER BL, PEREIRA BJ: Impact of intermittent hemodialysis variables on clinical outcomes in acute renal failure: A critical review. Am J Kidney Dis 35:980-991, 2000
43. KELLY KJ, WILLIAMS WWJ, COLVIN RB, BONVENTRE JV: Antibody to inter-cellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 91:812-816, 1994
44. KELLY K, MEEHAN S, COLVIN R, et al: Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int 56:922-931, 1999
45. HUANG X, KITCHING A, TIPPING P, HOLDSWORTH S: Interleukin-10 inhibits macrophage-induced glomerular injury. J Am Soc Nephrol 11:262-269, 2000
46. KITCHINO A, KATERELOS M, MUDGE S, et al: Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis. Clin Exp Immunol 128:36-43, 2002
47. GORMLEY SM, MCBRIDE WT, ARMSTRONG MA, et al: Plasma and urinary cytokine homeostasis and renal dysfunction during cardiac surgery. Anesthesiology 93:1210-1216, 2000
48. GORMLEY SM, MCBRIDE WT, ARMSTRONG MA, et al: Plasma and urinary cytokine homeostasis and renal function during cardiac surgery without cardiopulmonary bypass. Cytokine 17:61-65, 2002
49. HAN WK, BAILLY V, ABICHANDANI R, et al: Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 62:237-244, 2002
50. ICHIMURA T, HUNG C, YANG S, et al: Kidney injury molecule-1 (Kim-1): A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 286:F552-F563, 2004
51. SIMMONS E, HIMMELFARB J, SEZER M, et al: Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 65:1357-1365, 2004
52. IGLESIAS J, MARIK PE, LEVINE JS, NORASEPT II STUDY INVESTIGATORS: Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock. Am J Kidney Dis 41:62-75, 2003
53. LOISA P, RINNE T, LAINE S, et al: Anti-inflammatory cytokine response and the development of multiple organ failure in severe sepsis. Acta Anaesthesiol Scand 47:319-325, 2000
54. GUTTERIDGE J, MITCHELL J: Redox imbalance in the critically ill. Br Med Bull 55:49-75, 1999
55. AZUMI H, INOUE N, TAKESHITA S, et al: Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 100:1494-1498, 1999
56. WHITEHEAD A, FITZGERALD G: Twenty-first century phox: Not yet ready for widespread screening. Circulation 103:7-9, 2001
57. MACDONALD J, GALLEY H, WEBSTER N: Oxidative stress and gene expression in sepsis. Br J Anaesth 90;221-232, 2003
58. HOY A, LEININGER-MULLER B, KUTTER D, et al: Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 40:2-8, 2002
59. URSINI F, MAIORINO M, BRIGELIUS-FLOHE R, et al: Diversity of glutathione peroxidases. Methods Enzymol 252:38-53, 1995
60. ARTHUR J: The glutathione peroxidases. Cell Mol Life Sci 57:1825-1835, 2000
61. FLOHE L: Glutathione peroxidase. Basic Life Sci 49:663-668, 1988
62. SIES H: Glutathione and its role in cellular functions. Free Radic Biol Med 27:916-921, 1999
63. FORSBERG L, DE FAIRE U, MORGENSTERN R: Oxidative stress, human genetic variation, and disease. Arch Biochem Biophys 389:84-93, 2001
64. FUKAI T, FOLZ R, LANDMESSER U, HARRISON D: Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res 55:239-249, 2002
65. BALIGA R, UEDA N, WALKER P, SHAH S: Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 31:971-997, 1999
66. MCDONALD J, GALLET H, WEBSTER N: Oxidative stress and gene expression in sepsis. Br J Anaesth 90:221-232, 2003
67. DRUML W, SCHWARZENHOFER M, APSNER R, HORL W: Fat-soluble vitamins in patients with acute renal failure. Miner Electrolyte Metab 24:220-226, 1998
68. METNITZ P, FISCHER M, BARTENS C, et al: Impact of acute renal failure on antioxidant status in multiple organ failure. Acta Anaesthesiol Scand 44:236-240, 2000
69. BALAKRISHNAN V, BLUMBERG J, PEREIRA BJ, JABER BL: Antioxidant and oxidative stress indices in dialysis-dependent acute renal failure. Blood Purif 21:213-219, 2003
70. STORY A, RONCO C, BELLOMO R: Trace element and vitamin concentrations and losses in critically ill patients treated with continuous venovenous hemofiltration. Crit Care Med 27:220-223, 1999
71. YSEBAERT D, DE GREEF K, VERCAUTEREN S, et al: Identification and kinetics of leukocytes after severe ischaemia/reperfusion renal injury. Nephrol Dial Transplant 15:1562-1574, 2000
72. ALONSO A, LAU J, JABER B, et al: Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: A meta-analysis of randomized, controlled trials. Am J Kidney Dis 43:1-9, 2004
73. CONESA E, VALERO F, NADAL J, et al: N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol Regul Integr Comp Physiol 281:R730-R737, 2001
74. HEYMAN S, GOLDFARB M, SHINA A, et al: N-acetylcysteine ameliorates renal microcirculation: studies in rats. Kidney Int 63:634-641, 2003
75. WADDINGTON S, MOSLEY K, CATTELL V: Induced nitric oxide (NO) synthesis in heterologous nephrotoxic nephritis; effects of selective inhibition in neutrophil-dependent glomerulonephritis. Clin Exp Immunol 118:309-314, 1999
76. PARK K, BYUN J, KRAMERS C, et al: Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. J Biol Chem 278:27256-27266, 2003
77. YAMASHITA J, OGATA M, ITOH M, et al: Role of nitric oxide in the renal protective effects of ischemic preconditioning. J Cardiovasc Pharmacol 42:419-427, 2003
78. SCHRAMM L, LA M, HEIDBREDER E, et al: L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney Int 61:1423-1432, 2002
79. WILSON AG, DE VRIES N, POCIOT F, et al: An allelic polymorphism within the human tumor necrosis factor-alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177:557-560, 1993
80. MORSE H, OLOMOLAIYE O, WOOD N, et al: Induced heteroduplex genotyping of TNF-alpha, IL-1beta, IL-6 and IL-10 polymorphisms associated with transcriptional regulation. Cytokine 11:789-795, 1999
81. ABRAHAM LJ, KROEGER KM: Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 66:562-566, 1999
82. WILSON AG, SYMONS JA, MCDOWELL TL, et al: Effects of a polymorphism in the human tumor necrosis factor [alpha] promoter on transcriptional activation. Proc Natl Acad Sci 94:3195-3199, 1997
83. KROEGER KM, CARVILLE KS, ABRAHAM LJ: The -308 tumor necrosis factor-[alpha] promoter polymorphism effects transcription. Mol Immunol 34:391-399, 1997
84. WARZOCHA K, RIBEIRO P, BIENVENU J: Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91:3574-3581, 1998
85. Louis E, FRANCHIMONT D, PIRON A: Tumor necrosis factor gene polymorphism influences TNF-alpha production in lipopolysaccharide-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113:401-406, 1998
86. ABRAHAM L, Du D, ZAHEDI K, et al: Haplotypic polymorphisms of the TNFB gene. Immunogenetics 33:50-53, 1991
87. POCIOT F, MOLVIG J, WOGENSEN L, et al: A tumour necrosis factor beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus. Scand J Immunol 33:37-49, 1991
88. TABRIZI A, ZEHNBAUER B, FREEMAN B, BUCHMAN T: Genetic markers in sepsis. J Am Coll Surg 192:106-117, 2001
89. HEESEN M, KUNZ D, BACHMANN-MENNENGA B, et al: Linkage disequilibrium between tumor necrosis factor (TNF)-alpha-308 G/A promoter and TNF-beta NcoI polymorphisms: Association with TNF-alpha response of granulocytes to endotoxin stimulation. Crit Care Med 31:211-214, 2003
90. MIRA J-P, CARIOU A, GRALL F, et al: Association of TNF2, a TNF-[alpha] promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 282:561-568, 1999
91. TANG GJ, HUANG SL, YIEN HW, et al: Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 28:2733-2736, 2000
92. WEITKAMP JH, STUBER F, BARTMANN P: Pilot study assessing TNF gene polymorphism as a prognostic marker for disease progression in neonates with sepsis. Infection 28:92-96, 2000
93. WUNDERINK RG, WATERER GW, CANTOR RM, QUASNEY MW: Tumor necrosis factor gene polymorphisms and the variable presentation and outcome of community-acquired pneumonia. Chest 121:875, 2002
94. NADEL S, NEWPORT MJ, BOOY R, LEVIN M: Variation in the tumor necrosis factor-a promoter region may be associated with death from meningococcal disease. J Infect Dis 174:878-880, 1996
95. MCGUIRE W, HILL AV, ALLSOPP CE, et al: Variation of the TNF-[alpha] promoter region associated with susceptibility to cerebral malaria. Nature 371:508-510, 1994
96. CABRERA M, SHAW MA, SHARPLES C: Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 182:1259-1264, 1995
97. STUBER F, PETERSEN M, BOKELMANN F, SCHADE U: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 24:381-384, 1996
98. MAJETSCHAK M, FLOHE S, OBERTACKE U, et al: Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 230:207-214, 1999
99. YENDE S, QUASNEY MW, TOLLEY E, et al: Association of tumor necrosis factor gene polymorphisms and prolonged mechanical ventilation after coronary artery bypass surgery. Crit Care Med 31:133-140, 2003
100. SCHROEDER S, BORGER N, WRIGGE H, et al: A tumor necrosis factor gene polymorphism influences the inflammatory response after cardiac operation. Ann Thorac Surg 75:534-537, 2003
101. YENDE S, QUASNEY M, ZHANG Q, et al: Impact of cytokine gene polymorphisms on outcomes of coronary artery bypass graft surgery. Chest 121:868, 2002
102. SHAIKH K, YENDE S, WATERER GW, et al: Effect of tumor necrosis factor gene polymorphisms on restoration of body temperature after coronary artery bypass graft surgery. Chest 118:1098, 2000
103. JABER B, RAO M, Guo D, et al: Cytokine promoter gene polymorphisms and mortality in acute renal failure. Cytokine 25:212-219, 2004
104. DOMINICI R, CATTANEO M, MALFERRARI G, et al: Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. Immunogenetics 54:82-86, 2002
105. READ R, CANNINGS C, NAYLOR S, et al: Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 138:534-541, 2003
106. VIRTA M, HURME M, HELMINEN M: Increased frequency of interleukin-1beta (-511) allele 2 in febrile seizures. Pediatr Neurol 26:192-195, 2002
107. BERGER P, MCCONNELL J, NUNN M, et al: C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine 17:171-174, 2002
108. Cox A, CAMP N, NICKLIN M, et al: An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am J Hum Genet 62:1180-1188, 1998
109. SANTTILA S, SAVINAINEN K, HURME M: Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1[beta] production in vitro. Scand J Immunol 47:195-198, 1998
110. ANDUS T, DAIG R, VOGL D, et al: Imbalance of the interleukin 1 system in colonic mucosa-Association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2. Gut 41:651-657, 1997
111. TOUNTAS N, CASINI-RAGGI V, YANG H, et al: Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 117:806-813, 1999
112. VAMVAKOPOULOS J, GREEN C, METCALFE S: Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol 32:2988-2996, 2002
113. FANG X, SCHRODER S, HOEFT A, STUBER F: Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 27:1330-1334, 1999
114. MA P, CHEN D, PAN J, DU B: Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 30:1046-1050, 2002
115. WILKINSON R, PATEL P, LLEWELYN M, et al: Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. J Exp Med 189:1863-1874, 1999
116. AMOLI M, THOMSON W, HAJEER A, et al: Interleukin 1 receptor antagonist gene polymorphism is associated with severe renal involvement and renal sequelae in Henoch-Schonlein purpura. J Rheumatol 29:1404-1407, 2002
117. RAY K, CAMP N, BENNETT C, et al: Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes. Clin Sci (Lond) 103:303-310, 2002
118. BORGMANN S, ENDISCH G, HACKERU, et al: Proinflammatory genotype of interleukin-1 and interleukin-1 receptor antagonist is associated with ESRD in proteinase 3-ANCA vasculitis patients. Am J Kidney Dis 41:933-942, 2003
119. BARTON B: IL-6: insights into novel biological activities. Clin Immunol Immunopathol 85:16-20, 1997
120. FISHMAN D, FAULDS G, JEFFERY R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369-1376, 1998
121. FERRARI S, AHN-LUONG L, GARNERO P, et al: Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 88:255-259, 2003
122. FERNANDEZ-REAL JM, BROCH M, VENDRELL J, et al: Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 85:1331-1333, 2000
123. COX ED HS, DIMERCURIO BS, WESLEY RA, et al: Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 72:720-726, 2001
124. HEESEN M, OBERTACKE U, SCHADE F, et al: The interleukin-6 G(-174)C polymorphism and the ex vivo interleukin-6 response to endotoxin in severely injured blunt trauma patients. Eur Cytokine Netw 13:72-77, 2002
125. SCHLUTER B, RAUFHAKE C, ERREN M, et al: Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 30:32-37, 2002
126. GALLAGHER P, LOWE G, FITZGERALD T, et al: Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 58:154-156, 2003
127. HAHN A, KASTEN-JOLLY J, CONSTANTINO D, et al: TNF-alpha, IL-6, IFN-gamma, and IL-10 gene expression polymorphisms and the IL-4 receptor alpha-chain variant Q576R: effects on renal allograft outcome. Transplantation 72:660-665, 2001
128. BRULL DJ, MONTGOMERY HE, SANDERS J, et al: Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arteriosder Thromb Vasc Biol 21:1458-1463, 2001
129. BURZOTTA F, IACOVIELLO L, DI CASTELNUOVO A, et al: Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 88:1125-1128, 2001
130. TRESZL A, TOTH-HEYN P, KOCSIS I, et al: Interleukin genetic variants and the risk of renal failure in infants with infection. Pediatr Nephrol 17:713-717, 2002
131. HOMSI E, RIBEIRO-ALVES M, LOPES DE FARIA J, DIAS E: Interleukin-6 stimulates tubular regeneration in rats with glycerol-induced acute renal failure. Nephron 92:192-199, 2002
132. WESTENDORP RG LJ, HUIZINGA TW, ELOUALI AH, et al: Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:170-173, 1997
133. CRAWLEY E, KAY R, SILLIBOURNE J, et al: Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 42:1101-1108, 1999
134. VAN DER POL WL HT, VIDARSSON G, VAN DER LINDEN MW, et al: Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 184:1548-1555, 2001
135. PELLETIER R, PRAVICA V, PERREY C, et al: Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 70:674-680, 2000
136. GIRNDT M, SESTER U, SESTER M, et al: Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 14:2807-2810, 1999
137. LOWE PR, GALLEY HF, ABDEL-FATTAH A, WEBSTER NR: Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 31:34-38, 2003
138. HOLDSWORTH S, KITCHING A, TIPPING P: Chemokines as therapeutic targets in renal disease. Curr Opin Nephrol Hypertens 9:505-511, 2000
139. MODI W, DEAN M, SEUANEZ H, et al: Monocyte-derived neutrophil chemotactic factor (MDNCF/IL-8) resides in a gene cluster along with several other members of the platelet factor 4 gene superfamily. Hum Genet 84:185-187, 1990
140. JIANG Z, OKHUYSEN P, Guo D, et al: Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: Polymorphism in the IL-8 promotor region at position -251. J Infect Dis 188:506-511, 2003
141. HULL J, THOMSON A, KWIATKOWSKI D: Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 55:1023-1027, 2000
142. YU Y, CHADEE K: The 3′-untranslated region of human interleukin-8 mRNA suppresses IL-8 gene expression. Immunology 102:498-505, 2001
143. AMOLI MM, THOMSON W, HAJEER AH, et al: Interleukin 8 gene polymorphism is associated with increased risk of nephritis in cutaneous vasculitis. J Rheumatol 29:2367-2370, 2002
144. ROVIN B, LU L, ZHANG X: A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis. Kidney Int 62:261-265, 2002
145. ROVIN BH, LU L, SAXENA R: A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259:344-348, 1999
146. KIM H, LEE D, YANG S, et al: The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis 40:1146-1152, 2002
147. KRUGER B, SCHROPPEL B, ASHKAN R, et al: A Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 13:2585-2589, 2002
148. POLTORAK A, SMIRNOVA I, HE X, et al: Genetic and physical mapping of the Lps locus: Identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 24:340-355, 1998
149. POLTORAK A, HE X, SMIRNOVA I, et al: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282:2085-2088, 1998
150. HOSHINO K, TAKEUCHI O, KAWAI T, et al: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol 162:3749-3752, 1999
151. BIHL F, SALEZ L, BEAUBIER M, et al: Overexpression of toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J Immunol 170:6141-6150, 2003
152. ARBOUR N, LORENZ E, SCHUTTE B, et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25:187-191, 2000
153. CHILD N, YANG I, PULLETZ M, et al: Polymorphisms in toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem Soc Trans 31:652-653, 2003
154. AGNESE D, CALVANO J, HAHM S, et al: Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 186:1522-1525, 2002
155. LORENZ E, MIRA J, CORNISH K, et al: A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immunol 68:6398-6401, 2000
156. LORENZ E, MIRA J, FREES K, SCHWARTZ D: Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 162:1028-1032, 2002
157. BOCHUD P, HAWN T, ADEREM A: Cutting edge: A toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J Immunol 170:3451-3454, 2003
158. VILLAR J, MENDEZ-ALVAREZ S: Heat shock proteins and ventilator-induced lung injury. Curr Opin Crit Care 9:9-14, 2003
159. FEKETE A, TRESZL A, TOTH-HEYN P, et al: Association between heat shock protein 72 gene polymorphism and acute renal failure in premature neonates. Pediatr Res 54:452-455, 2003
160. SCHRODER O, SCHULTE K-M, OSTERMANN P, et al: Heat shock protein 70 genotypes HSPA1B and HSPA1L influence cytokine concentrations and interfere with outcome after major injury. Crit Care Med 31:76-79, 2003
161. ASEA A, KRAEFT S, KURT-JONES E, et al: HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 6:435-442, 2000
162. KELLY K: Stress response proteins and renal ischemia. Minerva Urol Nefrol 54:81-91, 2002
163. WATERER G, ELBAHLAWAN L, QUASNEY M, et al: Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. Crit Care Med 31:1367-1372, 2003
164. NATH K: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kid Dis 20:1-17, 1992
165. SHIRAISHI F, CURTIS L, TRUONG L, et al: Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol 278:F726-F736, 2000
166. BLYDT-HANSEN T, KATORI M, LASSMAN C, et al: Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury. J Am Soc Nephrol 14:745-754, 2003
167. Poss K, TONEGAWA S: Reduced stress defense in heme oxygenase deficient cells. Proc Natl Acad Sci USA 94:10925-10930, 1997
168. YACHIE A, NIIDA Y, WADA T, et al: Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 103:129-135, 1999
169. OTTERBEIN L, BACH F, ALAM J, et al: Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 6:422-428, 2000
170. LEE T-S, CHAU L-Y: Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 8:240-246, 2002
171. KUTTY R, KUTTY G, RODORIGUES I, et al: Chromosomal localization of the human heme oxygenase genes: heme oxygenase-1 (HMOX 1) maps to chromosome 22q12 and heme oxygenase-2 (HMOX 2) maps to chromosome 16p13.3. Genomics 20:513-516, 1994
172. LAVROVSKY Y, SCHWARTZMAN M, LEVERE R, et al: Identification of binding sites for transcription factors NF-kB and AP-2 in the promoter region of the human heme oxygenase-1 gene. Proc Natl Acad Sci USA 91:5987-5991, 1994
173. CHEN Y-H, LIN S, LIN M, et al: Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 111:1-8, 2002
174. EXNER M, SCHILLINGER M, MINAR E, et al: Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther 8:433-440, 2001
175. SCHILLINGER M, EXNER M, MLEKUSCH W, et al: Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. Thromb Res 106:131-136, 2002
176. YAMADA N, YAMAYA M, OKINAGA S, et al: Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 66:187-195, 2000
177. HAYES J, STRANGE R: Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. Free Radic Res 22:193, 1995
178. INOUE N, KAWASHIMA S, KANAZAWA K, et al: Polymorphism of the NADH/NADPH oxidase p22phox gene in patients with coronary artery disease. Circulation 97:135-137, 1998
179. GUZIK T, WEST N, BLACK E, et al: Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 102:1744-1747, 2000
180. ZAFARI A, DAVIDOFF M, AUSTIN H, et al: The A640G and C242T p22(phox) polymorphisms in patients with coronary artery disease. Antioxid Redox Signal 4:675-680, 2002
181. SCHNEIDER M, HILGERS K, HUANG Y, et al: The C242T p22phox polymorphism and endothelium-dependent vasodilation in subjects with hypercholesterolaemia. Clin Sci (Lond) 105:97-103, 2003
182. STANGER O, RENNER W, KHOSCHSORUR G, et al: NADH/NADPH oxidase p22 phox C242T polymorphism and lipid peroxidation in coronary artery disease. Clin Physiol 21:718-722, 2001
183. NAKANO T, MATSUNAGA S, NAGATA A, MARUYAMA T: NAD(P)H oxidase p22phox Gene C242T polymorphism and lipoprotein oxidation. Clin Chim Acta 335:101-107, 2003
184. WOLF G, PANZER U, HARENDZA S, et al: No association between a genetic variant of the p22(phox) component of NAD(P)H oxidase and the incidence and progression of IgA nephropathy. Nephrol Dial Transplant 17:1509-1512, 2002
185. RAIJMAKERS M, ROES E, STEEGERS E, PETERS W: The C242T-polymorphism of the NADPH/NADH oxidase gene p22phox subunit is not associated with pre-eclampsia. J Hum Hypertens 16:423-425, 2002
186. PIEDRAFITA F, MOLANDER R, VANSANT G, et al: An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271:14412-14420, 1996
187. PECOITS-FILHO R, STENVINKEL P, MARCHLEWSKA A, et al: A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int (Suppl 84):S172-S176, 2003
188. SANDSTROM J, NILSSON P, KARLSSON K, MARKLUND S: 10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. J Biol Chem 269:19163-19166, 1994
189. FORSBERG L, LYRENÄS L, DE FAIRE U, MORGENSTERN R: A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic Biol Med 30:500-505, 2001
190. SHEN Q, TOWNES P, PADDEN C, NEWBURGER P: An in-frame trinucleotide repeat in the coding region of the human cellular glutathione peroxidase (GPX1) gene: In vivo polymorphism and in vitro instability. Genomics 23:292-294, 1994
191. MOSCOW J, MORROW C, HE R, et al: Structure and function of the 5′-flanking sequence of the human cytosolic selenium-dependent glutathione peroxidase gene (hgpx1). J Biol Chem 267:5949-5958, 1994
192. FORSBERG L, DE FAIRE U, MARKLUND S, et al: Phenotype determination of a common Pro-Leu polymorphism in human glutathione peroxidase 1. Blood Cells Mol Dis 26:423-426, 2000
193. SEIDEGARD J, VORACHEK W, PERO R, PEARSON W: Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85:7293-7297, 1988
194. BOARD P: Biochemical genetics of glutathione-S-transferase in man. Am J Hum Genet 33:36-43, 1981
195. WIDERSTEN M, PEARSON W, ENGSTROM A, MANNERVIK B: Heterologous expression of the allelic variant mu-class glutathione transferases mu and psi. Biochem J 276:519-524, 1991
196. SEIDEGARD J, PERO R, MARKOWITZ M, et al: Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: A follow up study. Carciogenesis 11:33-36, 1990
197. ST PETER S, IMBER C, JONES D, et al: Genetic determinants of delayed graft function after kidney transplantation. Transplantation 74:809-813, 2002
198. HOBBS M, UDHAYAKUMAR V, LEVESQUE M, et al: A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet 360:1468-1475, 2002
199. NABEL E: Genomic medicine: Cardiovascular disease. N Engl J Med 349:60-72, 2003
200. RIDKER P, STAMPFER M: Assessment of genetic markers for coronary thrombosis: Promise and precaution. Lancet 353:687-688, 1999
201. CONSORTIUM TIH: The International HapMap Project. Nature 426:789-796, 2003
202. NEWMAN TB, BROWNER WS, HULLEY SB: Enhancing causal inference in observational studies, in Designing Clinical Research, edited by Hulley SB, Cummings SR, Baltimore, Williams & Wilkins, 1988, pp 98-109
203. ROSENTHAL N, SCHWARTZ R: In search of perverse polymorphisms. N Engl J Med 338:122-124, 1998
204. STUBER F: Another definite candidate gene for genetic predisposition of sepsis: Interleukin-10. Crit Care Med 31:314-315, 2003
205. JABER BL, LIANGOS O, PEREIRA B, BALAKRISHNAN V: Polymorphism of immuno-modulatory cytokine genes: Implications in acute renal failure. Blood Purif 22:101-111, 2004
206. BAILLY S, DI GIOVINEF, DUFF G: Polymorphic tandem repeat region in interleukin-1 alpha intron 6. Hum Genet 91:85-86, 1993
207. POCIOT F, MOLVIG J, WOGENSEN L, et al: A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 22:396-402, 1992
208. KANG T, LEE S, CHAE G: A polymorphism in the toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine 20:56-62, 2002
209. MCGUIRE W, KNIGHT J, HILL A, et al: Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis 179:287-290, 1999
210. ZHANG D, LI J, JIANG Z, et al: Association of two polymorphisms of tumor necrosis factor gene with acute severe pancreatitis. J Surg Res 112:138-143, 2003
211. ASENSI V, ALVAREZ V, VALLE E, et al: IL-1alpha (-889) promoter polymorphism is a risk factor for osteomyelitis. Am J Med Genet 119A:132-136, 2003
212. READ R, CAMP N, DI GIOVINE F, et al: An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 182:1557-1560, 2000
213. DELGADO J, BAENA A, THIM S, GOLDFELD A: Ethnic-specific genetic associations with pulmonary tuberculosis. J Infect Dis 186:1463-1468, 2002
214. LIN M, STORER B, MARTIN P, et al: Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349:2201-2210, 2003